MedTrace Logo

Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels

NCT00143234 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1825

Last updated 2021-01-27

No results posted yet for this study

Summary

The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines

Conditions

Interventions

DRUG

Amlodipine/atorvastatin single pill

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2005-07-31

Countries

  • Argentina
  • Australia
  • Brazil
  • Chile
  • Guatemala
  • Hong Kong
  • India
  • Indonesia
  • Israel
  • Jordan
  • Kuwait
  • Lebanon
  • Malaysia
  • Mexico
  • Morocco
  • Pakistan
  • Peru
  • Philippines
  • Saudi Arabia
  • Singapore
  • South Africa
  • South Korea
  • Taiwan
  • Thailand
  • Tunisia
  • Turkey (Türkiye)
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143234 on ClinicalTrials.gov